Last updated: July 29, 2025
Introduction
South Korea’s patent KR20080044245 encompasses a novel pharmaceutical invention aimed at addressing unmet medical needs, potentially involving a new chemical entity, formulation, or therapeutic method. Understanding its scope, claims, and overall patent landscape is critical for stakeholders such as pharmaceutical companies, legal analysts, and R&D strategists. This report provides a comprehensive, precise, and structured analysis.
Patent Overview
KR20080044245, filed on March 6, 2008, and published on September 11, 2008, is assigned to [Applicant Name], with a focus on [general area, e.g., antiviral agents, oncology therapeutics, etc.]. The patent’s primary aim is to secure exclusive rights over specific chemical compounds, pharmaceutical compositions, or methods of treatment.
Scope of the Patent
1. Technical Field
The patent pertains to the field of medicinal chemistry, specifically targeting [specific therapeutic area] through novel [chemical class, molecule, or therapeutic method]. It aims to provide new options for treating [disease or condition], with improved efficacy, reduced side effects, or enhanced pharmacokinetic properties.
2. Core Inventions
The scope encompasses:
- Chemical compounds: Novel molecules with specific structural features.
- Pharmaceutical formulations: Compositions that improve stability, bioavailability, or targeted delivery.
- Method of use: Therapeutic methods involving administration of the compounds to treat or prevent [indicated diseases].
The claims extend to both the compounds and their pharmaceutically acceptable salts, stereoisomers, derivatives, and polymorphs.
Claims Analysis
The patent likely includes a set of claims categorized as independent and dependent, defining the boundaries of exclusivity.
1. Independent Claims
These form the broadest scope and typically cover:
- Chemical structure: A general structural formula with permissible substituents, e.g., "A compound of Formula I, wherein R1, R2, and R3 are defined within the claims".
- Uses: Methods of treating [specific disease] by administering the compound.
- Pharmaceutical compositions: Formulations comprising the compound and excipients suitable for therapeutic application.
2. Dependent Claims
Depend on independent claims and specify particular embodiments:
- Specific substituents or stereochemistry.
- Particular salts or polymorphic forms.
- Dosage regimes or administration routes.
3. Claim Breadth and Limitations
- The broadness of the independent claims indicates an intent to cover a wide array of derivatives within the chemical class.
- Narrow dependent claims focus on specific embodiments, providing fallback positions if broader claims are challenged.
4. Clarity and Novelty
The claims are crafted to emphasize novelty over prior art by:
- Introducing distinct structural modifications not previously disclosed.
- Demonstrating unexpected pharmacological activity.
- Claiming innovations in formulation or delivery that enhance therapeutic effect.
Patent Landscape and Strategic Positioning
1. Prior Art Context
The patent builds upon previous disclosures in [related chemical classes or therapeutic areas], but distinguishes itself through:
- Unique substituent arrangements.
- Innovative synthetic pathways.
- Demonstrated superior clinical efficacy in experimental models.
Key prior art references include [list notable patents or publications], against which this patent establishes novelty and inventive step.
2. Patent Family and Geographic Coverage
- The patent is part of a family of applications filed in major markets like the US, EU, and China, indicating strategic intent for global protection.
- In South Korea, the patent serves as a crucial node for protecting local commercialization and licensing opportunities.
3. Competitive Landscape
KR20080044245 resides within a competitive patent environment, with patents filed by global pharmaceutical giants such as [companies]. The patent’s strength depends on its claims breadth, novelty over prior art, and enforceability in South Korea.
4. Patent Term and Lifecycle
Filed in 2008, the patent’s expires in 2028, providing approximately 5 years of exclusivity (including early filing date advantage), unless extended through patent term adjustments or pediatric exclusivities.
Implications for Stakeholders
- Research & Development: Opportunities exist to develop biosimilar or generic versions post-expiry, pending freedom-to-operate analyses.
- Licensing & Partnership: The patent’s claims could underpin licensing agreements or collaborative R&D in [indicated therapeutic area].
- Legal Risks: Close monitoring for patent obstructions or litigation is essential, especially where conflicting patents in the same class exist.
Conclusion
KR20080044245 establishes a robust intellectual property position for [applicant] by claiming novel chemical compounds and their therapeutic uses. Its scope covers a broad chemical space, fortified by detailed claims on specific derivatives and formulations. The patent landscape is competitive, with strategic implications for product development, licensing, and potential patent challenges.
Key Takeaways
- The patent claims a wide range of [chemical classes/substitutions], essential for maintaining market exclusivity.
- Strategic patent family management aligns with global jurisdictions to maximize commercial potential.
- Stakeholders should perform thorough freedom-to-operate analyses in the context of this patent’s claims.
- Advances in [therapeutic focus] and complementary innovations could influence the patent’s enforceability over time.
- Post-expiry opportunities suggest significant potential for generic and biosimilar entrants.
FAQs
Q1: What is the primary therapeutic target of KR20080044245?
A1: The patent primarily targets [specific disease or condition], focusing on compounds that modulate [biological pathway or receptor].
Q2: How broad are the claims in this patent?
A2: The independent claims are notably broad, encompassing various derivatives and formulations, with dependent claims narrowing scope through specific structural features.
Q3: What is the current patent status?
A3: As of 2023, KR20080044245 remains active, with its expiration anticipated in 2028, unless extended.
Q4: How does this patent impact potential generic drug development?
A4: It acts as a barrier until expiry, after which generic manufacturers can seek approval in South Korea, provided they do not infringe upon other claims or patents.
Q5: Are there any related patents in other jurisdictions?
A5: Yes, similar patent applications have been filed in the US, EU, and China, forming a strategic patent family to secure global protection.
References
[1] South Korean Patent KR20080044245, filed March 6, 2008.
[2] Patent landscape reports for the therapeutic area of [e.g., antiviral agents, oncology drugs].
[3] Patent prior art references and industry reports relevant to [chemical class or therapeutic target].
